论文部分内容阅读
抗氯喹恶性疟在大部分恶性疟流行区的出现给疟疾治疗提出了严重挑战,寻找新药迫在眉睫。中国研制的咯萘啶对恶性疟和间日疟均有较高疗效,已用于治疗抗氯喹恶性疟,但对中、西非恶性疟的作用未被研究,作者通过体外方法测定咯萘啶对中、西非恶性疟的作用,并与氯喹、单去乙基阿莫地喹和阿莫吡咯喹相比较。氯喹敏感株(L-3)和抗性株(FCM29)为实验室培养,31例1991年10月至1992年2月从中、西非回法国的感染疟疾旅行者在治疗前抽取静脉血,涂片染色镜检证实为单纯感染恶性疟且原虫密度≥0.1%者为试验对
The emergence of anti-chloroquine falciparum malaria in most endemic areas of falciparum malaria poses a serious challenge to the treatment of malaria and the search for new drugs is imminent. Pyronaridine developed in China has a high efficacy against both P. falciparum and P. vivax and has been used to treat P. falciparum resistant to chloroquine but has not been studied for P. falciparum in Central and Western Africa. West and Central Africa, the role of falciparum malaria, and with chloroquine, monoethyl detoximodamil and amoxicillin comparison. Chloroquine sensitive strains (L-3) and resistant strains (FCM29) were cultured in the laboratory and 31 malaria travelers from Central and West Africa back to France from October 1991 to February 1992 were drawn venous blood prior to treatment Dyeing microscopy proved to be purely infected with P. falciparum and protozoa density of 0.1% were tested